^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | prexasertib (ACR-368) (Chk2 inhibitor, Chk1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERa expression and proliferation in luminal primary and metastatic breast cancer cells
Published date:
04/13/2022
Excerpt:
Data revealed that ERα-positive BC cell lines are significantly more sensitive to all the CHK1 inhibitors analyzed (except for SB) than ERα-negative BC cell lines (Fig. 5A). The sensitivity to ATR inhibition is higher in ERα-positive than in the ERα-negative BC cell lines while no differences have been observed for BC cell lines treated with the ATM inhibitor KU. ERα-positive BC cell lines show increased sensitivity to Tam with respect to the ERα-negative BC cell lines (Fig. 5A’).
DOI:
10.1186/s13046-022-02360-y
